LAB vs TMO · rev $174.4M vs P/E 24, rev $44.56B
Standard Biotools Inc (LAB) versus Thermo Fisher Scientific Inc (TMO) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Thermo Fisher Scientific Inc (TMO) is a diagnostics & research company listed on US.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported TMO revenue for 2025-12-31 was $44.56B. Net income was $6.70B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
LAB currently screens at market cap $317.1M. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
Not investment advice. Open the LAB and TMO stock pages for the full models.
Not investment advice.